文献速递消化道肿瘤放疗放疗物理与技术

胰腺癌生物剂量提升放疗的作用

The role of biological dose-escalation for pancreatic cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-04-25

本文讨论局部晚期胰腺癌(LAPC)化疗放疗争议,LAP07研究显示化疗放疗虽未改善总生存但减少局部进展(p=0.03)。SBRT以25-35 Gy分3-5次可有效耐受地实现局部剂量提升,但BED10超过70 Gy未显著改善局部控制。SMART技术理论上最具进一步剂量提升潜力。

要点

  • LAP07研究显示化疗放疗减少局部进展(p=0.03)但无总生存获益。
  • SBRT在25-35 Gy分3-5次剂量下有效且可耐受。
  • BED10超过70 Gy未显著改善局部控制。

核心结论

  • 化疗放疗在LAPC中可减少局部进展,但总生存获益未证实。
  • SBRT是局部剂量提升最合适的方法,但BED10超过70 Gy未显著改善局部控制。
  • SMART技术理论上具有最高的进一步剂量提升潜力。

研究设计与样本

  • 本文为综述,讨论LAPC的化疗放疗和生物剂量提升。
  • SMART技术自2016年初在Amsterdam UMC已用于LAPC或局部复发胰腺癌,共300次治疗。

主要发现

  • LAP07研究中化疗放疗组局部进展减少(p=0.03)。
  • SBRT在25-35 Gy分3-5次剂量下有效且可耐受。
  • BED10超过70 Gy未显著改善局部控制。

关键数值与推荐

  • SBRT剂量25-35 Gy分3-5次。
  • BED10超过70 Gy未显著改善局部控制。

临床怎么用

  • SBRT可用于LAPC的局部剂量提升。
  • SMART技术可在线MR引导、无需植入标记、每日自适应计划,避免十二指肠、胃和肠道过高剂量。

局限性

  • 进一步剂量提升受邻近危及器官剂量限制。
  • BED10超过70 Gy未显著改善局部控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of chemo-radiotherapy for treatment of locally advanced pancreatic cancer (LAPC) has been discussed for many years, and the absence of an overall survival benefit compared to gemcitabine chemotherapy alone in the recent LAP07 study seems to have increased the controversy. However, even in this study, chemo-radiotherapy resulted in decreased local progression (p = 0.03). In combination with increased efficacy of novel systemic therapy consisting of oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX), radiation dose-escalation may show to be beneficial in LAPC. Stereotactic body radiation therapy (SBRT) can be expected to be the most suitable approach to perform local radiation dose-escalation, and has been shown to be both effective and tolerable at doses of 25-35 Gy in 3-5 fractions. Whether further dose-escalation for LAPC will be both feasible and useful is debatable, because of dose restrictions to adjacent critical organs at risk, and the observation that thus far a benefit of delivering BED10 in excess of 70 Gy has not shown to improve local control significantly. If an attempt to further dose-escalate is performed, stereotactic MR-guided adaptive radiation therapy (SMART) theoretically has the highest potential. In addition to superior soft-tissue setup without the need for implanted fiducial markers and online MR-guidance during delivery with minimal safety margins, daily plan adaptation directed at avoiding undue high doses to critical organs such as the duodenum, stomach and bowel are advantages of this technique over current SBRT. This paper aims to illustrate the SMART technique, which has been delivered in 300 fractions for LAPC or locally recurrent pancreatic cancer at Amsterdam UMC since early 2016.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bruynzeel AME, Lagerwaard FJ. The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol. 2019. PMID: 31341988. doi:10.1016/j.ctro.2019.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。